This bit is interesting "A portion of the operational savings will also be redirected to support the continued development of an expanding device portfolio. Unilife expects that as a result of this realignment, it could be in a position to secure development, industrialization or exclusivity agreements with interested pharmaceutical parties that can support the commercialization of some of these pipeline products during the second half of 2011" So some of the other stuff mentioned under "pipeline" on the website needs some $$. Sounds reasonable. And hopefully results in some good announcements :)
UNS Price at posting:
81.0¢ Sentiment: Hold Disclosure: Held